Barinthus Biotherapeutics
Stock Forecast, Prediction & Price Target
Barinthus Biotherapeutics Financial Estimates
Barinthus Biotherapeutics Revenue Estimates
Barinthus Biotherapeutics EBITDA Estimates
Barinthus Biotherapeutics Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | |
Revenue
% change YoY
| $268K N/A | $44.70M 16580.22% | $802K -98.20% | Avg: $500K Low: $500K High: $500K avg. -37.65% | Avg: $738.66K Low: $738.66K High: $738.66K avg. 47.73% | Avg: $186.49K Low: $186.49K High: $186.49K avg. -74.75% | |
Net Income
% change YoY
| $-50.86M N/A | $5.34M 110.50% | $-73.34M -1473.02% | Avg: $-82.78M Low: $-112.76M High: $-52.46M avg. -12.87% | Avg: $-76.48M Low: $-76.48M High: $-76.48M avg. 7.61% | Avg: $-98.66M Low: $-98.66M High: $-98.66M avg. -29.00% | |
EBITDA
% change YoY
| $-40.28M N/A | $5.19M 112.88% | $-74.81M -1540.96% | Avg: $-388.38K Low: $-388.38K High: $-388.38K avg. 99.48% | Avg: $-573.77K Low: $-573.77K High: $-573.77K avg. -47.73% | Avg: $-144.86K Low: $-144.86K High: $-144.86K avg. 74.75% | |
EPS
% change YoY
| -$1.37 N/A | $0.14 110.21% | -$1.91 -1464.28% | Avg: -$2.16 Low: -$2.94 High: -$1.37 avg. -12.91% | Avg: -$1.99 Low: -$1.99 High: -$1.99 avg. 7.61% | Avg: -$2.57 Low: -$2.57 High: -$2.57 avg. -29.00% | |
Operating Expenses
% change YoY
| $41.48M N/A | $47.50M 14.50% | $84.71M 78.33% | Avg: $14.60M Low: $14.60M High: $14.60M avg. -82.75% | Avg: $21.57M Low: $21.57M High: $21.57M avg. 47.73% | Avg: $5.44M Low: $5.44M High: $5.44M avg. -74.75% | |
FAQ
What is Barinthus Biotherapeutics stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of -11.42% in 2025-2027.
We have gathered data from 4 analysts. Their low estimate is -112.76M, average is -82.78M and high is -52.46M.
What is Barinthus Biotherapeutics stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of -21.55% in 2025-2027.
We have gathered data from 3 analysts. Their low revenue estimate is $500K, average is $500K and high is $500K.
What is Barinthus Biotherapeutics stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of -11.43% in 2025-2027.
We have gathered data from 4 analysts. Their low earnings per share estimate is -$2.94, average is -$2.16 and high is $-1.36.
What is the best performing analyst?
In the last twelve months analysts have been covering Barinthus Biotherapeutics stock. The most successful analyst is Carter Gould.